CENTRAL NERVOUS SYSTEM LYMPHOMA

This study is testing whether a combination of three drugs—thiotepa, pirtobrutinib, and sintilimab—can help control a type of lymphoma that affects the brain or has returned after previous treatment. It is for adults who are frail or whose cancer has not responded to standard the…

This early-stage study is testing whether combining two drugs, epcoritamab and ibrutinib, is safe for people with lymphoma that has returned in or spread to the brain after prior treatment. The main goal is to find a dose that causes few or manageable side effects. It will includ…

This early-stage study is testing the safety and initial effectiveness of a two-drug combination (loncastuximab tesirine and rituximab) given after a precise form of radiation therapy. It is for adults with lymphoma that has spread to or started in the brain or spinal cord, parti…

This study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …

This study is testing a new three-drug combination for adults with central nervous system lymphoma that has returned or not responded to prior treatment. The goal is to find a safe and effective dose of the oral drug selinexor when added to standard chemotherapy drugs (methotrexa…

This study aims to understand how whole brain radiation therapy affects memory, thinking, and quality of life in patients with blood cancers like lymphoma and leukemia. Researchers will follow 100 adult patients for up to 5 years, using standard memory tests, questionnaires, and …

This study aims to monitor the long-term health of 500 patients who have already received CAR-T cell therapy for various blood cancers in earlier trials. Researchers will follow these patients for up to 15 years to check for any late-developing side effects, such as new cancers o…